TOFIDENCE (tocilizumab) by Biogen is interleukin 6 receptor antagonists [moa]. First approved in 2023.
Drug data last refreshed 6h ago · AI intelligence enriched 1w ago
TOFIDENCE (tocilizumab) is a monoclonal antibody that blocks the interleukin-6 receptor, reducing inflammatory signaling in autoimmune and inflammatory conditions. It is administered as an injectable biologic and represents a targeted approach to modulating immune-driven disease pathology. The drug was approved by the FDA on September 29, 2023, entering a competitive IL-6 antagonist market.
Early-stage growth product with modest ASP trajectory; commercial teams are likely building market access and payer strategies to establish formulary positioning.
Interleukin 6 Receptor Antagonists
Interleukin-6 Receptor Antagonist
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)
Tocilizumab Discontinuation Versus Dose Reduction for Patients With Well-Controlled Giant Cell Arteritis
RCT of Tocilizumab for Anti-MDA5+DM
Interleukin-6 Guided Treatment With Dexamethasone or Tocilizumab in Patients Hospitalized With Acute Respiratory Symptoms - a Feasibility Study
Worked on TOFIDENCE at Biogen? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moTOFIDENCE represents a growth-stage biologic product with emerging commercial opportunity; roles span commercial strategy, payer negotiation, physician education, and market access. Career trajectory is positive for professionals building expertise in IL-6 antagonism, specialty pharma operations, and injectable biologic promotion.